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LONG-TERM OUTCOME OF METHOTREXATE-FREE GVHD PROPHY-
LAXIS USING SIROLIMUS AND TACROLIMUS IN MATCHED RELATED
(MRD) AND UNRELATED DONOR (URD) PERIPHERAL BLOOD STEM
CELL TRANSPLANTATION (PBSCT)
Cutler, C.1, Li, S.1, Ho, V.1, Koreth, J.1, Alyea, E.1, Soiffer, R.J.1,
Antin, J.H.1 1Dana-Farber Cancer Institute, Boston, MA.
We report here our long-term results of sirolimus and tacrolimus
without methotrexate (Mtx) after MRD and URD PBSCT. Meth-
ods: Transplanted subjects had HLA-A, B, C and DR1 matched
MRD and URD donors. Conditioning consisted of cytoxan (1800
mg/m2 x 2) and TBI (14 Gy, 7 fractions). Tacrolimus (serum conc.
5-10 ng/mL) and sirolimus (serum conc. 3-12 ng/mL) were given
without Mtx as GVHD prophylaxis. G-CSF (5 g/kg/day) was ad-
ministered from day12 until neutrophil engraftment if needed. Re-
sults 53 MRD and 30 URD recipients were transplanted between
7/2002 and 8/2005. The median number of stem cells infused was
lower in MRD recipients (7.6 106 vs. 10.2 106 CD34 cells/kg,
p0.001), however, neutrophil engraftment was similar (14 vs. 13.5
days, p0.2). Platelet engraftment to 20 106/ml (12 vs. 12 days,
p0.13) and to 100106/ml (17.5 vs. 17 days, p0.32) was similar in
the two cohorts. The median time to hospital discharge was 19 days
in both groups (p0.95), with only 2 deaths (2.4%) prior to discharge.
Transplant-related toxicity included acute lung injury (IPS/DAH,
n1, 1.2%), hepatic veno-occlusive disease (VOD, n7, 8.4%) and
thrombotic microangiopathy (TMA, n6, 7.3%). The cumulative
incidence of grade II-IV acute GVHD was 20.5%, and was not
different between cohorts (18.9 vs. 23.3%, p0.78). There were only
3 cases of grade III-IV acute GVHD (2 MRD, 1 URD). In a com-
peting risk model (relapse/death as competing risk) the cumulative
incidence of chronic GVHD was 52.4% and was not different be-
tween groups (50.9 vs. 53.3%, p0.67). The median follow-up of all
surviving patients is 32.8 months from transplantation. Non-relapse
mortality at 30 and 100 days was 0% and 4.8%. Relapse-free survival
for the entire group was 72.3% and 68.5% at 1 and 2 years (MRD
71.7% and 66.0%; URD 73.3% at both times, log rank p0.5).
Overall survival at 1 and 2 years is 77.1% and 72.2% (MRD 77.4%
and 69.8%; URD 76.7% at both times, log-rank p0.58). Causes of
death include relapse(13), VOD(4), late pulmonary disease(3),
GVHD(2), infection and organ failure(2).ConclusionsWe conclude
that sirolimus in lieu of Mtx with tacrolimus for GVHD prophylaxis
is associated with low transplant-related toxicity, low rates of acute
Summary of Major Clinical Endpoints
Combined MRD URD p
Engraftment (days)
ANC > 500 14 14 13.5 0.2
Plt > 20 000 12 12 12 0.13
Plt > 100 000 18 17.5 17 0.32
1st Discharge 19 19 19 0.95
GVHD
Acute Gr. II-IV 20.5% 18.9% 23.3% 0.78
Acute Gr. III-IV 3.6% 3.6% 3.3% 0.99
Chronic 52.4% 50.9% 53.3% 0.67
Survival
30-day NRM 0 0 0 NA
100-day NRM 4.8% 5.7% 3.3%
1-yr RFS 72.3% 71.7% 73.3% 0.5
2-yr RFS 68.5% 66.0% 73.3%
1-yr OS 77.1% 77.4% 76.7% 0.58
2-yr OS 72.2% 69.8% 76.7%
ANC  Absolute Neutrophil Count; Plt  Platelet; NRM 
Non-Relapse Mortality; RFS  Relapse-Free Survival; OS 
Overall Survival
GVHD and excellent outcomes. Moreover, MRD and URD out-
comes appear to be equivalent, suggesting that the historical dis-
parity in outcomes between MRD and URD transplantation can be
abrogated with effective GVHD prophylaxis.
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HIGH RECIPIENT CD4CD25HI REGULATORY T-CELL LEVEL PRE-
TRANSPLANT IS ASSOCIATED WITH REDUCED OVERALL SURVIVAL
AFTER UNRELATED DONOR HEMATOPOYETIC STEM CELL TRANSPLAN-
TATION
Prieto-Hinojosa, A.1, Madrigal, J.A.1, Shaw, B.E.1, Mayor, N.P.1,
Marsh, S.G.E.1, Travers, P.1, Duarte, R.F.2 1The Anthony Nolan
Research Institute, London, United Kingdom; 2ICO - Hospital Duran i
Reynals, Barcelona, Spain.
CD4CD25hi T-cells (T-regs) have been identiﬁed as a naturally
occurring regulatory T-cell population. T-regs express FOXP3,
produce anti-inﬂammatory cytokines such as TGF upon activa-
tion, and are essential to maintain tolerance. Their potential im-
pact on the alloreactive phenomena and the outcome of HSCT in
humans, however, remains controversial. We have analyzed the
effect of pre-conditioning peripheral blood levels of CD4CD25hi
T-regs on the outcome of 89 adult patients undergoing HLA-
identical (10/10) unrelated donor (UD)-HSCT. Allografts were
T-cell depleted with Alemtuzumab, which has been described to
preserve T-regs from depletion. The percentage of T-regs pre-
transplant had no effect on transplant related mortality or the
incidence of acute GVHD, but higher T-regs levels did associate
with a higher risk or relapse (p0.027) and the incidence of
chronic GVHD (p0.033). Overall, patients with a higher propor-
tion of CD4CD25hi T-cells had a reduced overall survival fol-
lowing UD-HSCT (30% vs 65%, median follow up 1013 days;
p0.002).
Although T-regs have been clearly identiﬁed by the expression of
the transcription repressor factor FOXP3 in mice, FOXP3 expres-
sion in humans is not restricted to CD4CD25hi T-cells. In a
healthy donor control group (n30), CD4CD25hi-expression
correlated well with both, FOXP3 mRNA-expression (r0.649;
p0.001) and TGF production (r0.912; p0.001), as previ-
ously described for T-regs. In preconditioning patient samples,
CD4CD25hi-expression had also a strong correlation with TGF
regulatory cytokine production (r0.863; p0.001), as well as an
inverse correlation with TNF expression (r-0.458; p0.001), in
keeping with a true regulatory phenotype. FOXP3 mRNA-expres-
sion, however, correlated neither with the CD4CD25hi T-regs
phenotype (r0.280; p0.040), nor with TGF production
(r0.229; p0.156), and appeared not be an accurate marker for
regulatory T-cell function in this patient setting.
In summary, preconditioning patient percentage of T-regs may
inﬂuence the outcome of UD-HSCT through their effect on
alloresponses against the tumour and the host. Accurate identiﬁ-
cation of T-regs in these patients requires the analysis of their
immunophenotype and expression of functional markers. FOXP3
expression, however, may not identify true regulatory T-cell func-
tion in patients undergoing UD-HSCT.
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ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HIV-
POSITIVE PATIENTS WITH MALIGNANT AND NON-MALIGNANT DISOR-
DERS: A REPORT FROM THE CENTER FOR INTERNATIONAL BLOOD
AND MARROW TRANSPLANT RESEARCH (CIBMTR)
Gupta, V.1, Tomblyn, M.1, Pederson, T.1, Thompson, J.1, Gress, R.1,
Storek, J.1, Burik, J.-A.1 van Horowitz, M.1, Keating, A.1 1CIBMTR
Infection and Immune Reconstitution Committee.
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Previous reports suggest feasibility of autologous transplantation
for HIV-associated lymphomas. Anecdotal reports suggest that
allogeneic hematopoietic stem cell transplantation (AlloHCT) also
may be feasible. To evaluate AlloHCT in HIV-positive patients,
we retrospectively analyzed 30 HIV-positive patients with malig-
nant (n22) or non-malignant disorders (n8), who received Al-
loHCT between 1987 and 2003 and were reported to the CIB-
MTR.
The median age at transplant was 34 years (range 9-49) and the
donors were: HLA identical siblings, 21 (70%); syngeneic, 5
(17%); and unrelated, 4 (13%). Indications for HCT included:
non-Hodgkin lymphoma, 11; chronic myeloid leukemia, 3; acute
myeloid leukemia, 3; myelodysplastic syndrome, 2; acute lympho-
blastic leukemia, 2; other acute leukemia, 1; aplastic anemia, 2; and
other non-malignant disorders including HIV disease, 6. Twenty-
two (73%) patients were transplanted prior to 1996. The condi-
tioning regimens included total body irradiation (TBI) containing,
16 (53%); and chemotherapy only, 14 (47%).
Rate of neutrophil engraftment at 28 days was 76%. The cumu-
lative incidence (95% CI) of grades II – IV acute GVHD (synge-
neic excluded) was 9% (1 – 23). For patients alive at 100 days (n 
12), the cumulative incidence of chronic GVHD at 1 and 2 years
was 42% (17 – 69). At a median follow-up of 55 months, 6 patients
are alive with a survival probability of 20% (10-33) at 2-years.
Treatment related mortality (TRM) at 100 days and 2-years were
46% (29 – 65) and 68% (50 – 84), respectively. Causes of TRM:
pulmonary toxicity, 8; infections, 4; organ failure, 4; HIV disease,
2; and others, 3. Deaths related to pulmonary toxicity appear to be
higher in patients receiving TBI based conditioning (6/16) com-
pared to the other conditioning regimens (2/14).
Of the available CD4 counts (x109/L) and viral loads (log copies)
data, median CD4 count (n  11) and viral load (n8) prior to
BMT was 137 and 2.1, respectively. At 3 months post BMT, the
median CD4 count (n 16) was 29. After 6 months post BMT, the
median CD4 count (n  9) and viral load (n  10) were 640 and
1.7, respectively.
Of the 8 patients transplanted after 1996, 4 survive compared to
2 of 22 transplanted prior to 1996, presumably related to the effect
of improved supportive care and HAART. These data suggest that
AlloHCT is feasible for HIV-positive patients with malignant and
non-malignant disorders and provide the framework for the design
of future prospective studies.
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A NEW STRATIFICATION STRATEGY THAT IDENTIFIES A HIGH RISK
SUBSET OF CLASS III PATIENTS AMONG CHILDREN WITH  THALAS-
SEMIA MAJOR UNDERGOING A MATCHED RELATED ALLOGENEIC STEM
CELL TRANSPLANTATION
Mathews, V.1, George, B.1, Lakshmi, K.M.1, Viswabandya, A.1,
Chandy, M.1, Srivastava, A.1 1Christian Medical College, Vellore,
Tamil Nadu, India.
The current risk stratiﬁcation of patients with  thalassemia major
undergoing an allogeneic SCT is based on liver size (2cm), presence
of liver ﬁbrosis and inadequate iron chelation (Lucarelli et al, NEJM
1990). Our clinical observation suggested that patients in Class III
(presence of all three adverse features) were a heterogeneous group.
We undertook a retrospective analysis to study the pre-transplant
variables that have an impact on outcome. Between 1991 and 2005,
190 patients underwent 197HLAmatched related allogeneic SCT for
a diagnosis of  thalassemia major at our center. Except for two cases,
all patients’ were less than 18 years of age at the time of transplant.
The majority (97.5%) of patients received a myeloablative (BuCy)
conditioning regimen. The median (	SD) age of this cohort was
7	4.1 years with 68% males. There were 11(5.6%), 81(41.1%) and
105(53.3%) in Lucarelli Class I, II and III respectively. The Kaplan-
Meier 5 year event free survival (event deﬁned as rejection, relapse or
death) for Class II and III patients’ was 78.53	4.53 and 51.97	5.14,
respectively. Only patient age and liver size as continuous variables
were signiﬁcantly associated with an adverse outcome. Using a ROC
curve plot analysis, cutoff values of 7 years and 5 cms respectively for
age and liver size gave the highest likelihood ratios for an adverse
effect on EFS (1.6 and 2.7 respectively). These cut off values signiﬁ-
cantly discriminated patients’ EFS on a univariate analysis. On a
forward stepwise multivariate analysis only age 7 years and liver
size  5 cms retained their signiﬁcance (RR 2.2 and 3.6, P-values
0.014 and 0.000 respectively). Using these two variables patients were
categorized as high risk if they were  7 years and had a liver size 
5 cms. There were 41 cases in this sub group (all were Class III). The
5 year EFS and OS in this high risk group (n41) was 23.93	6.88
and 39.01	7.96 while in the remaining Class III cases (n64) the 5
year EFS and OS was 73.23	5.56 and 81.22	4.89 (P0.000 for EFS
and OS). The majority of the events in the high risk group happened
in the ﬁrst 100 days [TRM17(41.4%), rejection3(7.3%) and death
from GVHD3(7.3%)]. Using age  7years and liver size  5 cms
we were able to identify a subset of patients in class III (39%) who
have a poor outcome with allogeneic SCT and would beneﬁt from
novel approaches while the remaining patients in Class III had out-
comes comparable to those in Class II.
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IMPACT OF PRE-TRANSPLANT SPLENECTOMY ON PATIENTS WITH 
THALASSEMIA MAJOR UNDERGOING A MATCHED RELATED ALLOGE-
NEIC STEM CELL TRANSPLANTATION
Mathews, V.1, George, B.1, Viswabandya, A.1, Lakshmi, K.M.1,
Chandy, M.1, Srivastava, A.1 1Christian Medical College, Vellore,
Tamil Nadu, India.
Pre-transplant splenectomy has the potential of reducing post
transplant transfusion requirement and hastening engraftment.
Impact of pre-transplant splenectomy in patients with  thalasse-
mia major undergoing an allogeneic SCT has never been ad-
dressed. Between 1991 and 2005, 190 patients underwent 197 HLA
matched related allogeneic SCT for a diagnosis of  thalassemia
major at our center. Patients had undergone a splenectomy at the
discretion of the referring physician. Twenty seven patients (29
transplants) had a pre-transplant splenectomy, they were all Luca-
relli Class III. The outcome of these patients was compared with
73 patients (76 transplants) in Class III who did not have a sple-
nectomy. Patients in the splenectomy group were older (11.7	5.0
years vs 8.5	3.5, P0.003) and had a larger liver size (5.7	1.8 cms
vs 4.4	1.6, P0.000). They were comparable for sex, FM, major
ABO mismatch, SGPT, Ferritin and presence of liver ﬁbrosis. Of
transplants that could be evaluated for engraftment (splenecto-
mized24, rest62), splenectomized patients had a signiﬁcantly
faster time to ANC  500/mm3 (15.4	5.9 days vs 17.5	4,
P0.002) and platelet20000/mm3 (22.5	6.7 days vs 32.5	13.6,
P0.000). The splenectomized group also had a signiﬁcantly re-
duced requirement of blood transfusion in the ﬁrst 100 days post
transplant (5.5	5.1 units vs 7.2	5.4, P0.017) and a trend to
reduced platelet transfusion requirement (59.7	58 units vs
71.8	55.7, P0.075). The rejections (early and late) were compa-
rable between the two groups (20.7% vs 14.5%, P0.55). Among
the splenectomized patients, 17 (63%) died, 1 following primary
graft failure, 7 secondary to RRT and 9 secondary to infective
complications after engraftment (including two late deaths on day
574 and 760 post transplant). On a univariate analysis age
(P0.02), liver size (P0.008) and splenectomy (P0.006) were
signiﬁcantly associated with reduced EFS (event deﬁned as primary
graft failure, rejection or death). On a multivariate analysis, adjust-
ing for age and liver size, splenectomy retained its signiﬁcant
adverse impact on EFS (RR 2.47, 95%CI 1.3 – 4.6, P0.004).
While pre-transplant splenectomy appeared to hasten engraftment
and reduce post transplant transfusion requirement this did not
translate into improved EFS. In this retrospective analysis, pre-
transplant splenectomy appears to be an independent adverse risk
factor in patients with  thalassemia major undergoing a HLA
matched related allogeneic SCT.
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EARLY HEMATOPOIETIC CHIMERISM PREDICTS ENGRAFTMENT AFTER
UMBILICAL CORD BLOOD STEM CELL TRANSPLANTATION
Moscardo´, F.1, Senent, L.1, Sanz, J.1, Planelles, D.2, Lorenzo, I.1,
Cervera, J.1, Jime´nez, C.1, Montesinos, P.1, Cantero, S.1, Sanz, M.A.1,
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